15 results about "Transplanted Organs" patented technology

A system and method for rendering a diseased organ implant eligible, the method including acquiring an image data set of a potential donor organ, identifying one or more disease states in the potential donor organ, wherein the one or more disease states render the organ ineligible for transplant, harvesting the potential donor organ, applying histotripsy therapy, and confirming elimination / reduction of the disease state in the potential donor organ.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

This invention belongs to the field of biomedical technology, specifically relating to a human-derived cell line for peritoneal metastasis of gastric cancer and its applications. The invention involves collecting ascites from gastric cancer patients and culturing it into organoids. These organoids are then transplanted subcutaneously into immunodeficient mice to form xenografts (PDOX). The transplanted organoids are digested and passaged in vitro to obtain a purified cell line. The primary isolated cell line is then inoculated into the peritoneal cavity of immunodeficient mice to induce the formation of metastatic ascites. Cells are extracted from the metastatic ascites and cultured again into organoids to construct human gastric cancer ascites cells, named BZGC. The cell line constructed in this invention has the ability to form 100% metastatic ascites in the mouse peritoneal cavity, fully simulating the entire process of ascites formation in gastric cancer peritoneal metastasis. The human-derived gastric cancer ascites cells described in this invention provide a stable, reliable, and highly clinically and pathologically similar in vitro and in vivo model for studying the mechanism of gastric cancer peritoneal metastasis, drug screening, and personalized treatment.

The invention discloses a lung tissue organoid culture method. The method comprises the following steps: firstly, carrying out three-dimensional differentiation culture on matrigel by utilizing lung basal cells in vitro to construct an organoid with alveolar epithelium characteristics; then, the organ is transplanted into the spleen of a recipient animal subjected to ectopic surgery (shifted to subcutaneous tissues). The rich blood vessel network and the unique microenvironment of the spleen greatly promote rapid vascularization, structural remodeling and functional maturation of organoids, and lung tissue highly simulating natural alveolus is formed. The invention overcomes the defects of insufficient vascularization and immature function of the existing organ-like model, provides an excellent in-vivo platform for researching lung development and disease mechanisms and carrying out drug screening and toxicological evaluation, and has important application value in the field of regenerative medicine.

An organ container includes a bag-shaped or tube-shaped insulating sheet. The insulating sheet has an opening and is capable of containing an organ inserted in an inner space through the opening. The insulating sheet is formed of an extra flexible material. The insulating sheet has a hardness less than or equal to F45 according to a durometer hardness test compliant with JIS K 6253-3:2012. Accordingly, in the transplantation of an organ with a variety of sizes and shapes into a recipient, the organ container is capable of covering the surface of the organ along the surface of the organ while holding the organ. The organ container suppresses a further outward spread of the organ, thereby ensuring the field of operation and reducing the possibility of interfering with the work of a surgeon.

The invention relates to the field of tumor animal models, in particular to a method for constructing an RC48 acquired drug-resistant in-situ gastric cancer mouse model and the RC48 acquired drug-resistant in-situ gastric cancer mouse model. The method comprises the following steps: S1, transplanting a tumor organ to the stomach of a target animal, carrying out animal living body imaging, and after a living body imaging numerical value reaches a certain threshold value, carrying out drug administration by using RC48; s2, performing animal living body imaging, drawing a tumor growth curve, killing the animal when the tumor growth curve is changed from a descending trend to a rising trend and an imaging numerical value after subsequent medication is not reduced any more, and performing digestion culture on the tumor tissue again to form a drug-resistant tumor organ; s3, transplanting the drug-resistant tumor organoid, so as to obtain the RC48 acquired drug-resistant in-situ gastric cancer mouse model. The animal model method constructs a drug-resistant animal model with complete immunization, in-situ tumor and RC48 drug treatment, is closer to the actual situation of a real case, and has more excellent guiding significance for drug research and development.

A method of use of a synthetic SCGB, and compositions thereof, to prevent the development or reduce the development of antibodies against a foreign antigen or set of antigens in the subject that receives the antigen(s) is provided. A synthetic SCGB being recombinant human CC10 protein is provided. The foreign antigen(s) is / are a cell, tissue or organ from a donor subject is administered, introduced, or transplanted into a recipient subject, a lung transplant, transplanted kidney, heart, liver, hematopoietic cell, or any other tissue or organ, antigen(s) is / are from human or non-human origin, purified therapeutic proteins or other drugs, food or drink, self-antigen or an allergen.

The copy number of the ten-gene edited porcine endogenous retroviruses (PERVs) in a whole genome is determined by ddPCR, and the PERV-Pol genotype is determined through second-generation whole genome deep sequencing. The method comprises the following steps: constructing a porcine PERV-Pol gene knockout targeting vector, co-transfecting the vector into a ten-gene edited porcine fetal fibroblast line, screening to obtain a PERV-Pol knockout fibroblast line, carrying out somatic cell nuclear transfer and embryo transfer, taking out a fetus during pregnancy, and identifying PERV-Pol gene knockout and PERVs inactivation conditions of the fetus. Furthermore, the continuous cloning technology is used for batch production of the PERVs completely inactivated eleven-gene edited xenotransplantation donor pigs. The technical problems that the PERV-Pol gene, especially the multi-copy gene, is high in editing difficulty, low in efficiency and long in period are solved, and the method has important significance on overcoming the problems of biosafety and immunological rejection in the xenogeneic organ transplantation process.

A method of storing a donor organ prior to implantation into an organ recipient includes bagging the donor organ by placing the donor organ into at least one bag and sealing the at least one bag; placing the bagged donor organ into a portable storage container; placing at least one cooling pack in the portable storage container, wherein the at least one cooling pack is configured to maintain a temperature of the donor organ at 8 to 12 degrees C. during storage of the donor organ, and storing the donor organ in the portable storage container prior to transplanting the donor organ into the organ recipient, wherein the portable storage container does not contain any ice at any time during storage of the donor organ.

Embodiments are directed to a method of treating acute radiation syndrome comprising administering to a subject following exposure to radiation a PIF peptide. Some embodiments describe a method of treating acute radiation syndrome following radiation exposure comprising transplanting bone marrow that has been exposed to a PIF peptide prior to transplantation into a subject. Other embodiments describe a method of increasing engraftment of a transplanted organ, tissue, or cell by pre-exposing the organ, tissue, or cell to a PIF peptide.

The present invention relates to methods for monitoring potential indications of allogeneic organ rejection by monitoring transplanted hair follicles from the same donor of a transplanted organ, and for performing or modifying immunosuppressive therapy to ameliorate or prevent the occurrence of acute or chronic organ rejection. The methods of the invention may also be used to select candidate allogeneic solid organ donors for recipients, as well as to improve the occurrence of acute rejection of transplanted allogeneic solid organs, such as kidneys.

The invention relates to the technical field of organ transplantation medical instruments, and particularly discloses a flow and pressure monitoring and control system for a perfusion process before donor lung acquisition. The system comprises an integrated disposable perfusion pipeline assembly, a multi-point pressure monitoring module, a flow adjusting module, a real-time feedback control module, a data storage and analysis module and a man-machine interaction module. A multi-point pressure interface and an electric control proportional valve are arranged in the integrated disposable perfusion pipeline assembly, and are matched with a reusable driving part, so that sterile safety and operation simplification are realized; the multi-point pressure monitoring module collects pressure data of positions such as a pulmonary artery inlet, a far end and a left atrium, and the flow adjusting module accurately adjusts the perfusion flow velocity based on an electric control proportional valve. The problems of insufficient perfusion precision, non-uniform distribution, lack of dynamic feedback, incomplete consumable design and the like in the prior art are solved, the donor lung perfusion safety and effectiveness are remarkably improved, and a guarantee is provided for successful lung transplantation.

The present invention relates to methods of administering therapeutic agents to a donor organ prior to transplant comprising circulating the therapeutic agent through the donor organ while maintaining the donor organ under ex vivo perfusion conditions, as well as methods of transplanting organs, biologically modifying a donor organ prior to transplant, and treating organ failure using the methods disclosed herein.

A system and method for rendering a diseased organ implant eligible, the method including acquiring an image data set of a potential donor organ, identifying one or more disease states in the potential donor organ, wherein the one or more disease states render the organ ineligible for transplant, harvesting the potential donor organ, applying histotripsy therapy, and confirming elimination / reduction of the disease state in the potential donor organ.